A New Standard for Medical Device Adverse Event Classification
|
|
|
- Cleopatra Hancock
- 9 years ago
- Views:
Transcription
1 Vol. 5, No. 12, December 2009 Can You Handle the Truth? A New Standard for Medical Device Adverse Event Classification By Nancy J. Stark Adverse events are defined and managed differently in the device world than in the drug world. These differences are among the most difficult concepts for pharmaceutical people to understand. In the pharmaceutical world, there is rarely a discussion of how to use the investigational product how to swallow a pill is self-evident to most of us. When you think of a device, imagine using a new cell phone or a new kitchen stove or a new car. What happens if you push the wrong button? What happens if you drop it on the floor? Can you break the baking dish if you turn the oven up too high? Can you break your finger if someone shuts the door on your hand? Medical devices are mechanical, electrical and software-driven things. Think about what goes wrong with such things in your daily life and you ll have a better idea of what can go wrong with medical devices. U.S. regulations (21 CFR Part 812 Investigational Device Exemptions) are now 30 years old and not the best place to start in order to understand adverse events for medical devices. Furthermore, the device world is actively pursuing global harmonization, so looking at the requirements for FDA alone gives only a limited perspective on this topic. Let s look at the new International Standards Organization (ISO) draft international standard ISO/DIS Clinical Investigation of Medical Devices in Human Subjects Good Clinical Practices (2009) and see how adverse events are classified in this document. When the new standard is officially published in 2010, it is expected to become the standard of practice around the world for medical device clinical research. A New Approach to Adverse Event Classification There have always been problems with adverse event classification in medical device clinical trials. Prior to the new draft standard, there was no mechanism for capturing complaints about devices that malfunctioned but did not result in subject injury. There was no mechanism for capturing investigator-use errors. There was no mechanism for capturing injuries to people who were not subjects. At the most basic level, this article discusses two types of events: those that qualify according to the new draft standard to be handled in the study sponsor s adverse event system and those that do not. Events that do not qualify are handled by the sponsor as customer service issues according to corporate policies. Those that do qualify are subject to reporting requirements under the new draft standard, government regulations, and institutional review board (IRB) and ethics committee requirements. Specific reporting requirements for sponsors and research sites vary by country and will not be discussed in this article. Decision Tree It will help the discussion if you follow along on the decision tree in Figure 1. The tree is an adaptation of Annex F of the 2009 ISO/DIS draft standard. It begins with the observation that an untoward medical occurrence in either a subject (where we consider investigational devices, device-related procedures or comparators 1 ) or other person (where we consider only the investigational device) has taken place, and progresses to classifying the complaint
2 or untoward medical occurrence as either a non-medical complaint, adverse event (AE), serious adverse event (SAE), adverse device effect (ADE), serious adverse device effect (SADE), or unanticipated serious adverse device effect (USADE). Figure 1. Decision Tree for Classification of Adverse Events Complaints (Box A) Complaints are written, electronic or oral communications that allege deficiencies about an investigational device s identity, quality, durability, reliability, safety or performance. 2 If an investigational device complaint might have led to an untoward medical occurrence if: (a) 2
3 suitable action had not been taken, (b) intervention had not been made, or (c) circumstances had been less fortunate, then it is handled under the sponsor s adverse event system. However, if the complaint is not related to the investigational device, say it is about a different commercial device used coincidentally in the study (the scalpel is dull, the bed is hard), it is handled as a customer service issue. Untoward Medical Occurrences (Box A) The decision tree in the draft standard starts with the phrase adverse event, but I find it confusing because the phrase is used again later in the standard to mean other things. To avoid confusion, I will borrow the opening phrase from the definition of adverse event untoward medical occurrence for Box A. According to the draft standard, an untoward medical occurrence is an unintended disease or injury or untoward clinical sign in a subject, caregiver or other person caused by or related to the investigational device, device-related procedure, or comparator. If the untoward medical occurrence does not involve a subject, only occurrences related to the investigational device are included in the definition and handled by the sponsor s adverse event system. As shown in Table 1, the draft standard requires that the sponsor s adverse event system handle anything bad that (a) happens to the subject or (b) involves an investigational device. Table 1. Complaints and Untoward Medical Occurrences Subject Caregiver Bystander No Injury (Non-medical complaint) Investigational Devices Device -related Procedures Comparator Devices Investigational Devices Untoward medical occurrences that are related to the investigational device and involve any person a subject, caregiver 3 (e.g., investigator, study nurse, primary physician, parent or spouse), or bystander (janitor, company technician, or any other person, regardless of their relationship) must be handled by the sponsor s adverse event system. Device-Related Procedure Untoward medical occurrences related to a device-related procedure and involving a subject must be captured by the sponsor s adverse event handling system. There is often a medical procedure involved in applying, implanting or using a device. The procedure itself the act of casting a broken bone or inserting a stent through the femoral artery may be the source of an untoward medical occurrence independent of the device. The procedure for implanting, deploying, operating, applying or otherwise using an investigational device is as much investigational as the device itself. It may be that no one 3
4 knows how to best use the investigational device, especially if it is a new technology. And, it is an accepted fact that investigators do not like to disclose device-related procedure occurrences because they feel it reflects badly on their competence. Only by requiring sponsors to capture the adverse event information can it be determined if cautions, precautions or warnings should be included in the device s labeling. Comparator Devices Untoward medical occurrences that are comparator-related and occur in subjects must be captured in the sponsor s adverse event handling system. In pharmaceutical trials, treatments are blinded, so handling adverse events related to the test article differently than those related to the control is not an option. Device trials are seldom blinded, so it is usually apparent whether the subject has received an investigational device or a comparator. Some have argued that capturing untoward medical occurrences from commercial comparator devices is unnecessary since they are already approved for sale. But that argument begs the question of why the trial is being done. Presumably, if there is a comparator device, the purpose of the trial is to compare the investigational device to it. It is necessary to capture untoward medical occurrences in comparator devices in order to make a safety comparison. Non-Medical Complaints (Box B) Not all complaints about investigational devices have to do with untoward medical occurrences, yet unless these complaints are captured there is no accurate way to assess device performance. If a complaint does not involve a subject or other person, it is obviously not medical and is called a non-medical complaint. According to the draft standard, nothing more must be done in the sponsor s adverse event system, although the sponsor should use the information appropriately. Table 2. Scenarios Leading to Non-Medical Complaints Device mislabeled, instructions-for-use unclear, wrong lot number Device malfunction Performance failure Investigator-use error Let s consider some scenarios that might lead to non-medical complaints. For example, a device may be mislabeled, the instructions-for-use may be unclear, or it may bear the wrong lot number. Labeling errors that, perhaps by luck, do not result in an untoward medical occurrence in a person are non-medical complaints. The device may malfunction during use. Malfunctioning may be as minor as a medical adhesive giving way too soon or as major as the lead of a pacemaker breaking. Neither event necessarily causes an untoward medical occurrence in a person, yet either event could be serious if the circumstances were right. The medical adhesive may be holding a life-supporting appliance in place. The broken pacemaker lead could prevent a critical electrical signal from reaching the heart. Device malfunctions that, even if by luck, do not result in a medical occurrence in a person are non-medical complaints. In a twist on the same concept, the device might simply fail to perform because of a design error. Nothing breaks, cracks or falls apart; the adhesive simply does not stick to skin or the pacemaker lead is too short. Devices that fail to perform as intended, yet do not result in an untoward medical occurrence in a person, are non-medical complaints. 4
5 In the final example, the device performs exactly as it is intended to perform, but the investigator makes an error in use. Suppose a reusable device is re-sterilized between uses but the re-sterilization process, itself, may cause the device to crack. The investigator is instructed to examine the device before each use to assure its physical integrity but fails to do so. The device is used on several occasions before damage is discovered. By luck, no one is injured. The event is a non-medical complaint if the investigator complains that the device isn t sufficiently durable. Adverse Events (Box C) Let s say the untoward medical occurrence did involve a subject or other person (Box B). The question then is whether the untoward medical occurrence (a) was related to the investigational device, device-related procedures or comparator, or (b) not. If not, and the occurrence is not serious, it is classified as an adverse event (AE). So, adverse events are non-device-related, non-serious medical occurrences. Notice that the word event is used for untoward medical occurrences not related to the investigational device, procedure or comparator. We shall see later that the word effect is used for occurrences related to or caused by the investigational device, procedure or comparator. Serious Adverse Events (Box C) Let s say the untoward medical occurrence was not related to the investigational device or procedure or comparator, but resulted in serious injury to a subject or other person; then the occurrence is classified as a serious adverse event (SAE). Table 3 presents examples. Serious Table 3. Examples of Serious Adverse Events in a Trial Investigating Intraocular Lenses Kidney ruptured in a bar fight Passenger in a car accident H1N1 flu Salmonella food poisoning A drug reaction Serious adverse events are untoward medical occurrences in a subject or other person that are not related to the investigational device, comparator, or trial procedures, but that meet the criteria of serious. The definition of serious remains unchanged from the 2003 ISO standard and is very similar to the ICH good clinical practice definition. A serious adverse event is one that: a) Led to a death, b) Led to a serious deterioration in the health of the subject that: 1) Resulted in a life-threatening illness or injury, or 2) Resulted in a permanent impairment of a body structure or a body function, or 3) Required in-patient hospitalization or prolongation of existing hospitalization, or 4) Resulted in medical or surgical intervention to prevent life threatening illness or injury or permanent impairment to a body structure or a body function, c) Led to fetal distress, fetal death, or a congenital abnormality or birth defect. A planned hospitalization for a pre-existing condition or a condition required by the protocol, without serious deterioration in health, is not considered serious. 4 5
6 Part 812 is More Lenient U.S. regulations for medical device trials 21 CFR Part 812 Investigational Device Exemptions do not automatically require reporting of adverse events and serious adverse events. This comes about partly because the regulations are 30 years old and partly in recognition that about half the trials conducted in the U.S. are on non-significant-risk devices, such as toothbrushes, endoscopes, intravascular catheters, mammography devices, and ureteral stents. 5 The FDA explicitly informs the sponsor if it wants to see adverse events and serious adverse events reported for significant risk studies. 6 Adverse Device Effects (Box D) Let s consider an untoward medical occurrence that happened in a subject or other person and is related to the investigational device or device procedure (but not the comparator). If the occurrence does not meet the definition of serious, it is classified as an adverse device effect (ADE). Adverse device effects are a subset of adverse events. Now, for the first time, we use the word effect in relation to a medical device adverse event, just as the word reaction is used in relation to a pharmaceutical adverse event. The phrase device effect is used with medical devices to convey the concept of cause and effect. Serious Adverse Device Effect (Box E) An untoward medical occurrence that happens in a subject or other person, is related to the investigational device, comparator, or procedure, and is serious, but is not unanticipated is a serious adverse device effect (SADE). Untoward medical occurrences that are not unanticipated, i.e. are unsurprising, are identified in the investigator s brochure or protocol and informed consent form. The phrase not unanticipated is used instead of anticipated because anticipated suggests that the untoward medical occurrence will occur, while not unanticipated suggests it might occur. One possible method of listing anticipated adverse device effects is to build a table like Table 4, in which the nature, severity, frequency of occurrence, and mitigation are presented. Later, this table can be used to establish whether or not a device effect was not unanticipated. Table 4. Example List of Potential Adverse Device Effects Nature of Effect Severity Frequency Mitigation Adhesive may dislodge Positive airway pressure device stops functioning during sleep Mild Common Frequent inspection. Replace or reinforce tape Usually mild but possible severe if subject stops breathing Rare Run function tests nightly before going to sleep Unanticipated Serious Adverse Device Effect (Box E) An untoward medical occurrence that happens in a subject or other person; is related to the investigational device, device procedure, or comparator; is serious; and was unanticipated is classified as an unanticipated serious adverse device effect (USADE). 6
7 U.S. and Japanese, but not European, medical device regulations include the USADE concept. Thus, if you are conducting studies with European investigators, extra training on this new concept is needed. Summary The new ISO/DIS draft standard brings welcome clarification and international harmonization to the classification of adverse events in medical device trials. The standard focuses attention on events most pertinent to human subjects protection. It will also streamline the activities of research sponsors, sites, IRBs, ethics committees, and regulators. As shown in Table 5, the classifications are logical and clear, although gray areas can always appear in practice. Table 5. Medical Device Adverse Event Classification Involves Person Involves Device, Procedure or Comparator Serious Unanticipated Non-medical complaint No Device n/a n/a Adverse Event (AE) Yes None of above No n/a Serious Adverse Event (SAE) Adverse Device Effect (ADE) Serious Adverse Device Effect (SADE) Unanticipated Serious Adverse Device Effect (SADE) Yes None of above Yes n/a Yes Any of above No n/a Yes Any of above Yes No Yes Any of above Yes Yes References and Notes 1. Device trials that use a control almost always use an active control called a comparator. In most cases, a placebo or no treatment arm is unethical. 2. ISO/DIS (2009) Section 3.11, definition of a complaint. 3. The draft standard uses the term users, rather than caregivers. 4. ISO/DIS (2009) Section FDA Information Sheet Guidance for IRBs, Clinical Investigators, and Sponsors; Significant Risk and Nonsignificant Risk Medical Device Studies CFR Part 812.3(m) defines a significant risk device as an investigational device that: (1) is intended as an implant and presents a potential for serious risk to the health, safety or welfare of a subject; (2) is purported or represented to be for a use in supporting or sustaining human life and presents a potential for serious risk to the health, safety or welfare of a subject; (3) is for a use of substantial importance in diagnosing, curing, mitigating or treating disease, or otherwise preventing impairment of human health, safety or welfare of a subject; or (4) otherwise presents a potential for 7
8 serious risk to the health, safety, or welfare of a subject. A nonsignificant risk device is an investigational device that is not significant risk. Author Nancy J. Stark, PhD, is founder and President of Clinical Device Group, a consulting and contracting firm for medical device pre-approval issues. Clinical Device Group is a CRO and conducts workshops on medical device clinical and regulatory issues. ( Contact her at or [email protected]. 8
GUIDELINES ON MEDICAL DEVICES
EUROPEAN COMMISSION DG Internal Market, Industry, Entrepreneurship and SMEs Consumer, Environmental and Health Technologies Health technology and Cosmetics MEDDEV 2.7/3 revision 3 May 2015 GUIDELINES ON
IOWA STATE UNIVERSITY Institutional Review Board. Reporting Adverse Events and Unanticipated Problems Involving Risks to Subjects or Others
IOWA STATE UNIVERSITY Institutional Review Board Reporting Adverse Events and Unanticipated Problems Involving Risks to Subjects or Others Introduction This policy details the Institutional Review Board
ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014
ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014 1. Introduction The St. Michael s Hospital (SMH) REB
Adverse Events in Clinical Trials: Definitions and Documentation
Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators Adverse Events in Clinical Trials: Definitions
GENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2):
Make copies of the blank SAE report form as needed. Retain originals with confirmation of all information faxed to DMID Pharmacovigilance Group Clinical Research Operations and Management Support (CROMS
Laurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute
Laurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute Understand the protocol completely Recognize institutional polices
Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events
Office for Human Research Protections (OHRP) Department of Health and Human Services (HHS) Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events
12.0 Investigator Responsibilities
v. 5.13.13 12.0 Investigator Responsibilities 12.1 Policy Investigators are ultimately responsible for the conduct of research. Research must be conducted according to the signed Investigator statement,
Vigilance Reporting. Vicky Medley - Head of QMS, Medical Devices. September 2015. Copyright 2015 BSI. All rights reserved.
Vigilance Reporting Vicky Medley - Head of QMS, Medical Devices September 2015 2 Why? 3 protecting and improving public health https://www.gov.uk/government/organisations/medicines-and-healthcareproducts-regulatory-agency/about
Patient Handbook on Stem Cell Therapies
Patient Handbook on Stem Cell Therapies Appendix I of the Guidelines for the Clinical Translation of Stem Cells www.isscr.org 2008, International Society for Stem Cell Research 2 Introduction We have all
PREP Course #27: Medical Device Clinical Trial Management
PREP Course #27: Medical Device Clinical Trial Management Presented by: Evelyn Huang Jeffrey Revello Office of Research Compliance North Shore-LIJ Health System CME Disclosure Statement The North Shore
PHARMACY AND POISONS ORDINANCE (Cap. 138) APPLICATION FOR A CLINICAL TRIAL/MEDICINAL TEST CERTIFICATE
PHARMACY AND POISONS ORDINANCE (Cap. 138) APPLICATION FOR A CLINICAL TRIAL/MEDICINAL TEST CERTIFICATE PART A: TRIAL INFORMATION A1. Title of Clinical Trial (as stated in proposed Protocol) Protocol No.
CDISC Data Standards Can Facilitate Composition of Adverse Event Narratives
CDISC Data Standards Can Facilitate Composition of Adverse Event Narratives Anisa Scott, Ph.D. and Richard C. Zink, Ph.D. JMP Life Sciences SAS Institute, Inc. [email protected] Copyright 2010 SAS Institute
Medicine Safety Glossary
The following definitions are provided as a resource to supplement the information provided in the Medicine Safety Education section of the Pfizer.com Web site; they are not intended as a comprehensive
Tracy Walker, RN, BSN, CCRP Research Nurse OHSU Knight Cancer Institute. 503-346-1183 [email protected]
Tracy Walker, RN, BSN, CCRP Research Nurse OHSU Knight Cancer Institute 503-346-1183 [email protected] Exercise Questions to Keep in Mind Is there an adverse event? What is the severity? What is the relationship
Guidance for Clinical Investigators, Sponsors, and IRBs
Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs Improving Human Subject Protection U.S. Department of Health and Human Services Office of the Commissioner (OC) Center
1. Study title Is the title self explanatory to a layperson? If not, a simplified title should be included.
These guidelines apply to all research projects where human subjects are involved in the study GUIDELINES FOR RESEARCHERS PATIENT INFORMATION SHEET & CONSENT FORM The guidance, which follows, applies primarily
CONTENTS SECTION TITLE PAGE
CONTENTS SECTION TITLE PAGE 1 Introduction 3 2 Scope 3 3 Abbreviations 4 4 Definitions 4 4.1 Medical device 4 4.2 Investigational medical device 4 4.3 Adverse event 5 4.4 Intensity 5 4.5 Serious adverse
JHSPH HUMAN SUBJECTS RESEARCH ETHICS FIELD TRAINING GUIDE
JHSPH HUMAN SUBJECTS RESEARCH ETHICS FIELD TRAINING GUIDE This guide is intended to be used as a tool for training individuals who will be engaged in some aspect of a human subject research interaction
Human Research Protection Program Good Clinical Practice Guidance for Investigators Investigator & Research Staff Responsibilities
This Guidance Document is to ensure that investigators and research personnel recognize their responsibilities associated with the conduct of human subject research by outlining their responsibilities,
Managing Risk in Clinical Research. Dr Martha J Wrigley R&D Manager Senior Visiting Fellow University of Surrey
Managing Risk in Clinical Research Dr Martha J Wrigley R&D Manager Senior Visiting Fellow University of Surrey Aim of the session To explore the risks associated with clinical research and understand how
Clinical Trial Compensation Guidelines
Clinical Trial Compensation Guidelines Preface These guidelines contain two distinct sections: Phase I Clinical Trials Compensation Guidelines Phases II, III and IV Clinical Trials Compensation Guidelines
Topics for today. Issues: Regulatory Obligations Post-marketing Adverse Event Reporting; MDRs and Safety Reports. Post-marketing Submissions
Issues: Regulatory Obligations Post-marketing Adverse Event Reporting; MDRs and Safety Reports Martha A. Feldman, RAC Drug & Device Development Co., Inc. Topics for today Post-approval requirements for
RESEARCH SUBJECT INFORMATION AND CONSENT FORM
1 1 1 1 1 1 1 0 1 0 1 0 RESEARCH SUBJECT INFORMATION AND CONSENT FORM TITLE: PROTOCOL NR: SPONSOR: INVESTIGATOR: WIRB VCU tracking number This template is based on a drug or device research study. The
Investigational Drugs: Investigational Drugs and Biologics
: I. PURPOSE The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics to ensure that adequate safeguards are in place
Medical Device Reporting (MDR) 21 CFR Part 803
Medical Device Reporting (MDR) 21 CFR Part 803 1 Objectives Review applicable sections of 21 CFR 803 and 21 CFR 820 Review and explain MDR reporting requirements Review FDA-483 observation examples 2 Medical
Vertex Investigator-Initiated Studies Program Overview
Vertex Investigator-Initiated Studies Program Overview Our Goal To support independent, investigator-initiated research designed to advance scientific knowledge of disease states, patient populations,
Medical Device Reporting (MDR) Requirements the New FDA Draft Guidance
Medical Device Reporting (MDR) Requirements the New FDA Draft Guidance February 27, 2014 Jeffrey K. Shapiro (202) 737-9633 [email protected] 1 Essential Requirements n Submit MDR reportable events to FDA
Guidance Notes for Applicants of the Certificate for Clinical Trial on Medical Device
Guidance Notes for Applicants of the Certificate for Clinical Trial on Medical Device List of Contents Page 1. Introduction 1.1 The Medical Device Administrative Control System and the 3 proposed legislation
Good Clinical Practice 101: An Introduction
Good Clinical Practice 101: An Introduction Presented by: Lester Jao Lacorte, MD Medical Officer Commissioner s Fellow Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological
PMAs, 510(k)s, and Advanced IDE Topics
PMAs, 510(k)s, and Advanced IDE Topics Kenneth J. Cavanaugh Jr., Ph.D. Scientific Reviewer Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health [email protected]
APPENDIX I-A: INFORMED CONSENT BB IND 11184 Protocol CDC IRB #4167
APPENDIX I-A: INFORMED CONSENT BB IND 11184 Protocol CDC IRB #4167 INFORMED CONSENT FOR USE OF DIPHTHERIA ANTITOXIN (DAT) FOR SUSPECTED DIPHTHERIA CASES Investigational New Drug (IND) BB 11184 Protocol
Sarah Chandler A/Head, Regulatory and Scientific Section Medical Devices Bureau [email protected]
Software Regulated as a Medical Device Sarah Chandler A/Head, Regulatory and Scientific Section Medical Devices Bureau [email protected] Therapeutic Products Directorate Director General S. Sharma
GOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE
ICH E6 GCP: Consolidated Guideline: Investigator 1/7 Institutional Review Board Services ICH HARMONIZED TRIPARTITE GUIDELINE E6: GOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE 4. INVESTIGATOR 4.1 Investigator's
Family Caregiver s Guide to Hospice and Palliative Care
Family Caregiver Guide Family Caregiver s Guide to Hospice and Palliative Care Even though you have been through transitions before, this one may be harder. If you have been a family caregiver for a while,
Clinical Trials: What You Need to Know
Clinical Trials: What You Need to Know Clinical trials are studies in which people volunteer to test new drugs or devices. Doctors use clinical trials to learn whether a new treatment works and is safe
Data Management in Clinical Trials
Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research February 19, 2013 Diane St. Germain, RN, MS Nurse Consultant Division of Cancer Prevention National Cancer
Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure
703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a
Research Ethics Review Committee (WHO ERC)
Research Ethics Review Committee (WHO ERC) 20, AVENUE APPIA CH-1211 GENEVA 27 SWITZERLAND HTTP://INTRANET.WHO.INT/HOMES/RPC/ERC HTTP://WWW.WHO.INT/RPC/RESEARCH_ETHICS Informed Consent Template for Clinical
FMEA Failure Risk Scoring Schemes
FMEA Failure Risk Scoring Schemes 1-10 Scoring for Severity, Occurrence and Detection CATEGORY Severity 10 9 8 7 6 5 3 2 1 Hazardous, without warning Hazardous, with warning Very High High Moderate Low
Guide for Research Sites Seeking Accreditation
Guide for Research Sites Seeking Accreditation (For research sites that only conduct research and do not have their own IRBs) November 16, 2010 Purpose of the Guide The accreditation process for most research
OECD Recommendation on the Governance of Clinical Trials
OECD Recommendation on the Governance of Clinical Trials Marketing authorisation status of the medicinal products Non-authorised medicine Authorised medicine, treatment regimen outside
RESEARCH PARTICIPANT INFORMED CONSENT AND PRIVACY AUTHORIZATION FORM
If you are using Epic for this study, fax a copy of the signed consent form to 410-367-7382. Patient I.D. Plate RESEARCH PARTICIPANT INFORMED CONSENT AND PRIVACY AUTHORIZATION FORM Protocol Title: Application
Paris, 15 June 2013 Response to a public consultation
Paris, 15 June 2013 Response to a public consultation Revision of the World Medical Association Helsinki Declaration: - transparency of clinical trial results must be enhanced (articles 23, 24 & 26) -
INVESTIGATOR HANDBOOK
INVESTIGATOR HANDBOOK Liberty IRB, Inc. 1450 S. Woodland Blvd., Suite 300A Deland, Florida 32720 Phone (386) 279-4318 Fax: (386)868-4563 Website: www.libertyirb.com Business hours: Monday Friday, 8:00am
CDRH Regulated Software
CDRH Regulated Software An Introduction John F. Murray Jr. CDRH Software Compliance Expert CDRH Regulates Software in the following areas Medical Devices Automation of Production Systems Automation of
Guidance notes. for Patient Safety and Pharmacovigilance in Patient Support Programmes
Guidance notes for Patient Safety and Pharmacovigilance in Patient Support Programmes 9 May 2011 Approval Status Authors The ABPI Pharmacovigilance Expert Network Change History N/A Approval Date 9 May
2.2 Roles and Responsibilities in the Conduct and Assessment of Clinical Trials
L1 2.2 Roles and Responsibilities in the Conduct and Assessment of Clinical Trials Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager,
Classifying Adverse Events From Clinical Trials
Classifying Adverse Events From Clinical Trials Bernard LaSalle, Richard Bradshaw University of Utah, Biomedical Informatics, Salt Lake City, UT USA [email protected] Abstract The use of adverse
THE INDIVIDUAL AND SOCIAL MODELS OF DISABILITY
THE INDIVIDUAL AND SOCIAL MODELS OF DISABILITY MIKE OLIVER BA PhD READER IN DISABILITY STUDIES THAMES POLYTECHNIC Paper presented at Joint Workshop of the Living Options Group and the Research Unit of
Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors
Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors Frequently Asked Questions About Medical Devices Additional copies are available from: Office of Good Clinical Practice Office
Risk Management Plan (RMP) Guidance (Draft)
Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Translated by Pharmaceuticals and Medical Devices Agency Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour
Comparing GCP Requirements for Medical Device Clinical Trials in the US and Japan
REGULATORY MANAGER Comparing GCP Requirements for Medical Device Clinical Trials in the US and Japan By Harmonization-by-Doing Working Group 4 Introduction The convergence of US and Japanese medical device
University of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol
University of Hawai i Human Studies Program Guidelines for Developing a Clinical Research Protocol Following are guidelines for writing a clinical research protocol for submission to the University of
Clinical Trials and Safety Surveillance of Drugs in Development
Clinical Trials and Safety Surveillance of Drugs in Development Hoda Eid, M.Sc., Ph.D. Manager, ADR Unit Office of Clinical Trials Therapeutic Products Directorate [email protected] Overview Clinical
Consent Form: Example 2 (DNA Sequencing)
Consent Form: Example 2 (DNA Sequencing) Important note: This model language was developed for the NHGRI Medical Sequencing Project (MSP). It is included here only as an example of how to describe a sequencing
Guidance for Industry and Investigators
Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and
Guideline on good pharmacovigilance practices (GVP)
1 2 20 February 2012 EMA/876333/2011 3 4 Guideline on good pharmacovigilance practices (GVP) Annex I - Definitions Draft finalised by the Agency in collaboration with Member States 7 February 2012 Definitions
GEORGIA ADV ANCE DIRECTIV E FOR HEALTH
GEORGIA ADV ANCE DIRECTIV E FOR HEALTH CARE Advance Directives: Your Right To Decide Georgia law gives competent adults the right to make choices about their own health care. This includes the right to
Guidance For Research Involving Human Embryonic Stem Cells, Germ Cells, And Cells Obtained From Cord Blood
Guidance For Research Involving Human Embryonic Stem Cells, Germ Cells, And Cells Obtained From Cord Blood Supreme Council of Health Department of Research Guidance Regarding Research Involving Human Embryonic
Study Start-Up SS-204.01. STANDARD OPERATING PROCEDURE FOR Site Initiation Visit (SIV)
Study Start-Up SS-204.01 STANDARD OPERATING PROCEDURE FOR Site Initiation Visit (SIV) Approval: Nancy Paris, MS, FACHE President and CEO 08 March 2012 (Signature and Date) Approval: Frederick M. Schnell,
CHAPTER 2 APPROACH TO THE INCIDENT
CHAPTER 2 APPROACH TO THE INCIDENT Reassuring the casualty is very important in first aid and the best reassurance for both casualty and bystanders is a confident first aider taking decisive action. In
Things You Should Know About Adverse Event Report Data
U.S. Department of Health and Human Services Food and Drug Administration Center for Food Safety and Applied Nutrition CFSAN Adverse Event Reporting System Voluntary Reports on Red Bull Energy Drink January
Cardio-Pulmonary Resuscitation (CPR): A Decision Aid For. KGH Patients And Their Families
Cardio-Pulmonary Resuscitation (CPR): A Decision Aid For KGH Patients And Their Families The goal of this pamphlet is to provide information about cardiopulmonary resuscitation (CPR) so you can be adequately
CONDUCTING GLOBAL CLINICAL RESEARCH TRIALS:
CONDUCTING GLOBAL CLINICAL RESEARCH TRIALS: COMPARING AND CONTRASTING FDA MEDICAL DEVICE REGULATIONS FOR CLINICAL INVESTIGATORS WITH ISO 14155:2011 Introduction Today s clinical research landscape for
Special Considerations for Pediatric Trials
Special Considerations for Pediatric Trials Clinical research with minors poses several significantly different issues than research conducted on adults. Therefore, researchers must address a number of
ICH Topic E 2 A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. Step 5
European Medicines Agency June 1995 CPMP/ICH/377/95 ICH Topic E 2 A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting Step 5 NOTE FOR GUIDANCE ON CLINICAL SAFETY DATA MANAGEMENT:
Standard Operating Procedures
Standard Operating Procedures Ffff H a r v a r d L o n g w o o d M e d i c a l A r e a Office of Human Research Administration 90 Smith St. Suite 335 Boston, MA 02120 617-432-3071/ 617-432-2157 www.hsph.harvard.edu/ohra
Patient Information Leaflet: Part 1 select-d
Patient Information Leaflet: Part 1 select-d Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism Introduction This
What Is Patient Safety?
Patient Safety Research Introductory Course Session 1 What Is Patient Safety? David W. Bates, MD, MSc External Program Lead for Research, WHO Professor of Medicine, Harvard Medical School Professor of
Lesson 7: Respiratory and Skeletal Systems and Tuberculosis
Glossary 1. asthma: when the airways of the lungs narrow, making breathing difficult 2. bacteria: tiny living creatures that can only be seen with a microscope; some bacteria help the human body, and other
STANDARD OPERATING PROCEDURES FOR GOOD CLINICAL PRACTICE
STANDARD OPERATING PROCEDURES FOR GOOD CLINICAL PRACTICE UNC OB/GYN (V.1) 9.1.2014 Page i TABLE OF CONTENTS INTRODUCTION. iii ABBREVIATIONS iv GLOSSARY v LISTING OF ATTACHMENTS.... xi I. 1.0 GENERAL ADMINISTRATION
This unit will provide the structure needed to achieve successful supervision and oversight of the study. We will explain the importance of an
Music No audio Please review information shown to understand the general course navigation and available resources. Resources, such as the audio script, example forms, and website links, can be accessed
PROGRAM OVERVIEW OSHA RECORDKEEPING SAFETY PROGRAM REGULATORY STANDARD - OSHA - 29 CFR 1904
PROGRAM OVERVIEW OSHA RECORDKEEPING SAFETY PROGRAM REGULATORY STANDARD - OSHA - 29 CFR 1904 INTRODUCTION: Records provide employers and OSHA with statistical data to determine where emphasis should be
MULTICARE ASSOCIATES OF THE TWIN CITIES, P.A. NOTICE OF PRIVACY PRACTICES
MULTICARE ASSOCIATES OF THE TWIN CITIES, P.A. NOTICE OF PRIVACY PRACTICES THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED AND HOW YOU CAN GET ACCESS TO THIS INFORMATION.
Series 1 Case Studies Adverse Events that Represent Unanticipated Problems: Reporting Required
Welcome! This document contains three (3) series of Case Study examples that will demonstrate all four OHSU reporting categories (#1 4) as well as examples of events that are considered not reportable.
Clinical Investigator Inspections and FDA-483 Observations
Clinical Investigator Inspections and FDA-483 Observations Nancy A. Bellamy, Investigator Bioresearch Specialist/ BIMO Coordinator FDA Detroit District Office October 2, 2013 Objectives Background on FDA
Medicals c i e n t i f i c study
Medicals c i e n t i f i c study design risks medical-ethics review board 2 Table of contents M e d i c a l - s c i e n t i f i c study Preface 2 Introduction 4 Medical-scientific study 5 Why participate?
Questions from GAQC Conference Call The Impact of SAS 112 on Governmental Financial Statement Audits January 4, 2007
Questions from GAQC Conference Call The Impact of SAS 112 on Governmental Financial Statement Audits January 4, 2007 Preparing Financial Statements Q1. During a recent AICPA Webcast, a panelist indicated
CENTER FOR CONNECTED HEALTH POLICY
CENTER FOR CONNECTED HEALTH POLICY The Center for Connected Health Policy (CCHP) is a public interest nonprofit organization that develops and advances telehealth policy solutions to promote improvements
Script/Notes for PowerPoint Presentation. Medication Use Safety Training for Seniors (MUST for Seniors)
Script/Notes for PowerPoint Presentation Medication Use Safety Training for Seniors (MUST for Seniors) Instructions: You can use the following script to help you prepare your remarks to your organization
Device Accountability in Clinical Research
Office of Human Research Device Accountability in Clinical Research Managing research device inventory & tracking Objectives Define device accountability Review the two main categories of research devices
What is Obstructive Sleep Apnoea?
Patient Information Leaflet: Obstructive Sleep Apnoea Greenlane Respiratory Services, Auckland City Hospital & Greenlane Clinical Centre Auckland District Health Board What is Obstructive Sleep Apnoea?
Clinical trials for medical devices: FDA and the IDE process
Clinical trials for medical devices: FDA and the IDE process Owen Faris, Ph.D. Deputy Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health,
What is a medical device? Medical Devices: Roadmap to Market. Kathryn Klaus, Esq.
Medical Devices: Roadmap to Market Kathryn Klaus, Esq. The last installment of Regulatory 360 discussed the FDA organization in general where it came from and a broad overview of how it operates, as well
Complaints, Servicing, and FDA Reporting
Complaints, Servicing, and FDA Reporting Dan O Leary CBA, CQA, CQE, CRE, SSBB, CIRM President Ombu Enterprises, LLC [email protected] www.ombuenterprises.com 603-358-3082 1 Outline Setting the Stage
Causality Assessment in Practice Pharmaceutical Industry Perspective. Lachlan MacGregor Senior Safety Scientist F. Hoffmann-La Roche Ltd.
Causality Assessment in Practice Pharmaceutical Industry Perspective Lachlan MacGregor Senior Safety Scientist F. Hoffmann-La Roche Ltd., Basel Disclaimer: The opinions expressed in this presentation are
Evaluation and Assessment and Eligibility Regulations 2011
303.10 Developmental delay. As used in this part, developmental delay, when used with respect to an individual residing in a State, has the meaning given to that term under 303.300. 303.10 Developmental
Research Involving Human Biological Materials: Ethical Issues and Policy Guidance Executive Summary
Research Involving Human Biological Materials: Ethical Issues and Policy Guidance Executive Summary Introduction Biomedical researchers have long studied human biological materials such as cells collected
Principal Investigator and Sub Investigator Responsibilities
Principal Investigator and Sub Investigator Responsibilities I. Purpose To define the roles and responsibilities of Principal Investigators conducting research at GRU. II. Definition The term Principal
Administrative Policies and Procedures for MOH hospitals /PHC Centers. TITLE: Organization & Management Of Medication Use APPLIES TO: Hospital-wide
Administrative Policies and Procedures for MOH hospitals /PHC Centers TITLE: Organization & Management Of Medication Use APPLIES TO: Hospital-wide NO. OF PAGES: ORIGINAL DATE: REVISION DATE : السیاسات
Medical Record Documentation and Legal Aspects Appropriate to Nursing Assistants
We hope you enjoy this course. Most folks print a copy of the test and circle the answers while reading through the course. You can then log into your account (if you created one), enter your answers online,
